These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10758302)

  • 1. Toxicity in head and neck cancer: a review of trends and issues.
    Trotti A
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):1-12. PubMed ID: 10758302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment.
    Bensadoun RJ; Magné N; Marcy PY; Demard F
    Eur Arch Otorhinolaryngol; 2001 Nov; 258(9):481-7. PubMed ID: 11769997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system.
    Palazzi M; Tomatis S; Orlandi E; Guzzo M; Sangalli C; Potepan P; Fantini S; Bergamini C; Gavazzi C; Licitra L; Scaramellini G; Cantu' G; Olmi P
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):330-7. PubMed ID: 17881148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.
    Trotti A; Bellm LA; Epstein JB; Frame D; Fuchs HJ; Gwede CK; Komaroff E; Nalysnyk L; Zilberberg MD
    Radiother Oncol; 2003 Mar; 66(3):253-62. PubMed ID: 12742264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients.
    Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer.
    Hartley A; Sanghera P; Kazi W; Mehanna H; McConkey C; Glaholm J; Fowler J
    Clin Oncol (R Coll Radiol); 2011 Feb; 23(1):29-33. PubMed ID: 20829006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent platinum-based chemotherapy and hyperfractionated radiotherapy with late intensification in advanced head and neck cancer.
    Glicksman AS; Wanebo HJ; Slotman G; Liu L; Landmann C; Clark J; Zhu TC; Lohri A; Probst R
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):721-9. PubMed ID: 9336155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.
    Fu KK; Cooper JS; Marcial VA; Laramore GE; Pajak TF; Jacobs J; Al-Sarraf M; Forastiere AA; Cox JD
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):425-38. PubMed ID: 8655364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer.
    Kitamoto Y; Akimoto T; Ishikawa H; Nonaka T; Katoh H; Nakano T; Ninomiya H; Chikamatsu K; Furuya N
    Jpn J Clin Oncol; 2005 Nov; 35(11):639-44. PubMed ID: 16275679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy.
    Geara FB; Peters LJ; Ang KK; Garden AS; Tucker SL; Levy LB; Brown BW
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):455-62. PubMed ID: 8655367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity antagonists in head and neck cancer.
    Trotti A
    Semin Radiat Oncol; 1998 Oct; 8(4):282-91. PubMed ID: 9873106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer.
    Franco P; Martini S; Di Muzio J; Cavallin C; Arcadipane F; Rampino M; Ostellino O; Pecorari G; Garzino Demo P; Fasolis M; Airoldi M; Ricardi U
    Med Oncol; 2017 May; 34(5):81. PubMed ID: 28386836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients.
    De Crevoisier R; Bourhis J; Domenge C; Wibault P; Koscielny S; Lusinchi A; Mamelle G; Janot F; Julieron M; Leridant AM; Marandas P; Armand JP; Schwaab G; Luboinski B; Eschwege F
    J Clin Oncol; 1998 Nov; 16(11):3556-62. PubMed ID: 9817275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.
    Skladowski K; Maciejewski B; Golen M; Tarnawski R; Slosarek K; Suwinski R; Sygula M; Wygoda A
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):706-13. PubMed ID: 17011446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system.
    El-Sayed S; Nabid A; Shelley W; Hay J; Balogh J; Gelinas M; MacKenzie R; Read N; Berthelet E; Lau H; Epstein J; Delvecchio P; Ganguly PK; Wong F; Burns P; Tu D; Pater J
    J Clin Oncol; 2002 Oct; 20(19):3956-63. PubMed ID: 12351592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.